{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T06:41:58Z","timestamp":1791009718841,"version":"4.1.0"},"reference-count":32,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2004,1,15]]},"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p>To determine the objective response rate, duration of remission and toxicity of octreotide alone or with the later addition of prednisone in patients with unresectable, advanced thymic malignancies in whom the pretreatment octreotide scan was positive.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p>Forty-two patients with advanced thymoma or thymic carcinoma were entered onto the trial, of whom 38 were fully assessable (one patient had inconclusive histology; three patients had negative octreotide scan). Patients received octreotide 0.5 mg subcutaneously tid. At 2 months, patients were evaluated. Responding patients continued to receive octreotide alone; patients with progressive disease were removed from the study. All others received prednisone 0.6 mg\/kg orally qid for a maximum of 1 year.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Two complete (5.3%) and 10 partial responses (25%) were observed (four partial responses with octreotide alone; the remainder with octreotide plus prednisone). None of the six patients without pure thymoma responded. The 1- and 2-year survival rates were 86.6% and 75.7%, respectively. Patients with an Eastern Cooperative Oncology Group performance status of 0 lived significantly longer than did those with a performance status of 1 (P = .031).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Octreotide alone has modest activity in patients with octreotide scan\u2013positive thymoma. Prednisone improves the overall response rate but is associated with increased toxicity. Additional studies with the agent are warranted.<\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.2004.02.047","type":"journal-article","created":{"date-parts":[[2004,1,13]],"date-time":"2004-01-13T23:33:14Z","timestamp":1074036794000},"page":"293-299","source":"Crossref","is-referenced-by-count":174,"title":["Octreotide Alone or With Prednisone in Patients With Advanced Thymoma and Thymic Carcinoma: An Eastern Cooperative Oncology Group Phase II Trial"],"prefix":"10.1200","volume":"22","author":[{"suffix":"Sr","given":"Patrick J.","family":"Loehrer","sequence":"first","affiliation":[{"name":"From the Indiana University Medical Center and The Walther Cancer Institute, Indianapolis, IN; Harvard School of Public Health and Dana-Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; and The Johns Hopkins University, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[{"name":"From the Indiana University Medical Center and The Walther Cancer Institute, Indianapolis, IN; Harvard School of Public Health and Dana-Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; and The Johns Hopkins University, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H.","family":"Johnson","sequence":"additional","affiliation":[{"name":"From the Indiana University Medical Center and The Walther Cancer Institute, Indianapolis, IN; Harvard School of Public Health and Dana-Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; and The Johns Hopkins University, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Ettinger","sequence":"additional","affiliation":[{"name":"From the Indiana University Medical Center and The Walther Cancer Institute, Indianapolis, IN; Harvard School of Public Health and Dana-Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; and The Johns Hopkins University, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1","unstructured":"Cameron RB, Loehrer PJ, Thomas CR Jr: Neoplasms of the mediastinum, in DeVita VT, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology (ed 6) . Philadelphia, PA, Lippincott-Raven, pp 1019,2001-1036"},{"key":"R2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.7.2280"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.1007\/BF00181765"},{"key":"R4","unstructured":"Lastoria S, Vergara E, Palmieri G, et al: In vivo detection of malignant thymic masses by indium-111-DTPA-D-Phe-octreotide scintigraphy. J Nucl Med 39:634,1998-639,1"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1210\/endo.140.1.6398"},{"key":"R6","doi-asserted-by":"crossref","unstructured":"Fuller PJ, Verity K: Somatostatin gene expression in the thymus gland. J Immunol 143:1015,1989-1017,","DOI":"10.4049\/jimmunol.143.3.1015"},{"key":"R7","doi-asserted-by":"crossref","unstructured":"Timsit J, Savino W, Safieh B, et al: Growth hormone and insulin-like growth factor-1 stimulate hormonal function and proliferation of thymic epithelial cells. J Clin Endocrinol Metab 75:183,1992-188,","DOI":"10.1210\/jcem.75.1.1619008"},{"key":"R8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3083.1993.tb01719.x"},{"key":"R9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199701233360405"},{"key":"R10","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"R12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.9.3093"},{"key":"R13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.6.1164"},{"key":"R14","unstructured":"Bruns C, Stolz B, Raulf F, et al: Somatostatin receptor expression: Therapeutic considerations. J Endocrinol Invest 20:2,1997-4,"},{"key":"R15","doi-asserted-by":"crossref","unstructured":"Reisine T, Bell GI: Molecular biology of somatostatin receptors. Endocr Rev 16:427,1995-442,","DOI":"10.1210\/edrv-16-4-427"},{"key":"R16","doi-asserted-by":"publisher","DOI":"10.1172\/JCI118618"},{"key":"R17","doi-asserted-by":"crossref","unstructured":"Delesque N, Buscail L, Esteve JP, et al: A tyrosine phosphatase is associated with the somatostatin receptor. Ciba Found Symp 190:187,1995-196,","DOI":"10.1002\/9780470514733.ch12"},{"key":"R18","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.92.5.1580"},{"key":"R19","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.91.6.2315"},{"key":"R20","doi-asserted-by":"publisher","DOI":"10.1016\/S0026-0495(96)90077-3"},{"key":"R21","doi-asserted-by":"publisher","DOI":"10.1016\/0163-7258(93)90009-3"},{"key":"R22","unstructured":"Szepeshazi K, Schally AV, Halmos G, et al: Targeting of cytotoxic somatostatin analog AN-238 to somatostatin receptor subtypes 5 and\/or 3 in experimental pancreatic cancers. Clin Cancer Res 7:2854,2001-2861,"},{"key":"R23","unstructured":"Plonowski A, Schally AV, Nagy A, et al: Inhibition of metastatic renal cell carcinomas expressing somatostatin receptors by a targeted cytotoxic analogue of somatostatin AN-238. Cancer Res 60:2996,2000-3001,"},{"key":"R24","unstructured":"Kiaris H, Schally AV, Nagy A, et al: Regression of U-87 MG human glioblastomas in nude mice after treatment with a cytotoxic somatostatin analog AN-238. Clin Cancer Res 6:709,2000-717,"},{"key":"R25","unstructured":"Khanna C, Prehn J, Hayden D, et al: A randomized controlled trial of octreotide pamoate long-acting release and carboplatin versus carboplatin alone in dogs with naturally occurring osteosarcoma: Evaluation of insulin-like growth factor suppression and chemotherapy. Clin Cancer Res 8:2406,2002-2412,"},{"key":"R26","unstructured":"Burch PA, Block M, Schroeder G, et al: Phase III evaluation of octreotide versus chemotherapy with 5-fluorouracil or 5-fluorouracil plus leucovorin in advanced exocrine pancreatic cancer: A North Central Cancer Treatment Group Study. Clin Cancer Res 6:3486,2000-3492,"},{"key":"R27","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(99)00177-X"},{"key":"R28","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(95)90157-4"},{"key":"R29","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.10239"},{"key":"R30","doi-asserted-by":"publisher","DOI":"10.1097\/00003072-199901000-00006"},{"key":"R31","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-129-2-199807150-00006"},{"key":"R32","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19811201)48:11<2485::AID-CNCR2820481123>3.0.CO;2-R"},{"key":"R33","doi-asserted-by":"publisher","DOI":"10.1007\/s002590050034"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2004.02.047","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T18:33:46Z","timestamp":1682620426000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2004.02.047"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,1,15]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2004,1,15]]}},"alternative-id":["10.1200\/JCO.2004.02.047"],"URL":"https:\/\/doi.org\/10.1200\/jco.2004.02.047","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,1,15]]}}}